The Wall Street Journal - February 28, 2011
Daiichi Sankyo has acquired Plexxikon for 805 million dollars. The deal will help the Japanese company to get some co-promotion rights in the U.S. for PLX4032, cancer in advanced stage of experimentation, developed by Roche and Plexxikon. The agreement provides for any payment up to $ 130 million related to the approval of the drug .
0 comments:
Post a Comment